Cellectar Biosciences, Inc.
CLRB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.04 | -0.10 | 0.04 |
| FCF Yield | -435.49% | -98.19% | -210.92% | -61.98% |
| EV / EBITDA | 0.23 | -0.64 | 0.25 | -0.05 |
| Quality | ||||
| ROIC | -320.19% | 294.21% | -283.65% | -72.36% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.07 | 0.76 | 0.88 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -43.46% | -30.62% | -12.06% | -62.27% |
| Safety | ||||
| Net Debt / EBITDA | 0.44 | 0.23 | 0.67 | 1.48 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |